Serotonin syndrome risk with psilocybin — what's real and what's myth

Genuine serotonin syndrome from psilocybin alone is extremely rare if it exists at all. Psilocybin is a serotonin 2A agonist — it works primarily at the 2A receptor, not by flooding the synapse with serotonin the way SSRIs, SNRIs, or MDMA do. Classic serotonin syndrome requires serotonin excess; psilocybin's mechanism doesn't produce this directly. The theoretical concern is real with MDMA, which does flood the synapse — psilocybin is different.

The realistic concern is psilocybin + MAOI combinations. MAOIs inhibit the breakdown of psilocin and serotonin, significantly amplifying and prolonging effects. Combining psilocybin with an MAOI (including the harmalas in ayahuasca, or pharmaceutical MAOIs like phenelzine) can produce unpredictably intense and extended experiences. This combination requires careful dosing and should only be undertaken with experience in both substances individually. The risk here is overwhelm, not serotonin syndrome per se.

SSRI interactions: SSRIs significantly blunt psilocybin's effects in most people (5-HT2A downregulation from chronic SSRI use reduces psilocybin binding). This isn't exactly a safety concern — it means the psilocybin won't work as expected, not that it's dangerous. Some people on SSRIs report needing 2-4x their usual dose to have any effect. Stopping SSRIs to restore psilocybin sensitivity requires tapering under medical supervision — never abrupt discontinuation.